RE: The idiots are winning22 May 2024 13:29
Bfd: "They also wish to compare Ava6000 to the LFT, a product which never even got to market. Why anybody would do that is also beyond me. It's chalk and cheese."
A couple of things, as I particularly refer back to the LFT.
It did get to market it just never sold. But also on its way to being a flop it was highlighted by AVCT as being the best test in the world with lots of commercial interest with deals being inked, tie ups with other companies, distributors in place at al. So before we knew it was a flop all the data from the science said it was a fantastic world beater. (Bams and Elisa were also heralded as commercial products filling a need in the market.) Also just as relevant, was the constant delay in getting the LFT approved.
The fact that they all flopped is not the issue.
The reason I refer back is the communication about those products.
For whatever reason the communications about how good the products were, never materialised. The constant delays for approval were never explained.
This is exactly how this trial has progressed, constant delays never explained. As a result the veracity of the science can be brought into question as it is following the same pattern.
So rather than say chalk and cheese, right now the comparison is the same.
The basis of my now increasing scepticism, is not just the coms but the fact that the trial had 7 dose increases the last 3 being unexpected,( and almost certainly a 7th not needed, but we had to have anyway), followed by a short 2WD out of the blue announcement with what looks like a delay in the very first reporting timeline.
I honestly don't understand why anyone thinks this is going to plan or exceeding expectations based on the history of how the company reports "progress" with how this seems to be following the same pathway.
Also if it were so good the raise would not have been at 50p. Also, that would have been, if the data was already so good, the bargain of the sentry with buyers falling over themselves to get in, but has fallen another 20%.
Where has the data-rich release been? No peer review remember.
And the silence from CC, because the silence only means that there is nothing to say. You can bet at 40p with another sell off a couple of months away she needs the SP bolstered, so there is no argument for silence.
Anyway, its not about the LFT per se, its about how AVCT communicate to the market and they have disappointed from the get-go and have continued to do so through this trial
Sign In
Follow the stocks
